文献速递儿童内分泌与遗传代谢

英国高HbA1c的1型糖尿病儿童混合闭环胰岛素泵治疗真实世界结局

Real-world outcomes of hybrid closed-loop insulin pump therapy in UK children and young people with type 1 diabetes and high HbA1c: a multicentre retrospective cohort study.
PubMed 文献 · Arch Dis Child · 2026-09-18

这项多中心回顾性队列研究纳入220例HbA1c≥69 mmol/mol的≤19岁1型糖尿病儿童和青少年,评估启动混合闭环(HCL)胰岛素泵治疗后的HbA1c变化。HCL启动后HbA1c从基线均值82.5 mmol/mol显著下降至3个月内72.8 mmol/mol,12个月时69.3 mmol/mol,所有亚组均改善,糖尿病相关住院减少。

要点

  • HCL启动后HbA1c显著下降,3个月内从82.5降至72.8 mmol/mol,12个月时69.3 mmol/mol。
  • 基线HbA1c极高(>100 mmol/mol)和从每日多次注射转换者改善最大。
  • 不同HCL泵系统间结局相似,糖尿病相关住院总体减少。

核心结论

  • 在高HbA1c的1型糖尿病儿童和青少年真实世界队列中,启动HCL治疗与血糖控制持续改善和糖尿病相关住院减少相关。

研究设计与样本

  • 多中心回顾性观察性队列研究,纳入英国13个NHS儿科糖尿病单位。
  • 纳入≤19岁、1型糖尿病病程超过1年、HCL启动时及至少3个月前HbA1c≥69 mmol/mol的儿童和青少年,共220例。

主要发现

  • HCL启动后HbA1c显著下降(p<0.001),从基线均值82.5 mmol/mol降至3个月内72.8 mmol/mol,12个月时69.3 mmol/mol。
  • 所有亚组均观察到改善,基线HbA1c极高(>100 mmol/mol)和从每日多次注射转换者降幅最大。
  • 不同HCL泵系统间结局相似,糖尿病相关住院总体减少。

临床怎么用

  • 对于HbA1c≥69 mmol/mol的1型糖尿病儿童和青少年,可考虑启动HCL胰岛素泵治疗以改善血糖控制。
  • 基线HbA1c极高或使用每日多次注射者可优先考虑转换至HCL治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate changes in glycated haemoglobin (HbA1c) following initiation of hybrid closed-loop (HCL) insulin pump therapy in children and young people (CYP) with previously elevated HbA1c in a real-world multicentre setting. DESIGN: Retrospective multicentre observational cohort study. SETTING: 13 National Health Service paediatric diabetes units within a regional diabetes network in England, UK. PATIENTS: CYP aged ≤19 years with type 1 diabetes of more than 1 year's duration and HbA1c ≥69 mmol/mol at the time of HCL initiation and at least 3 months prior. INTERVENTIONS: Initiation of HCL insulin pump therapy. MAIN OUTCOME MEASURES: Primary outcome was change in HbA1c following HCL initiation. Secondary outcomes included subgroup and pump system comparisons and changes in diabetes-related hospital admissions. RESULTS: A total of 220 participants were included. HbA1c decreased significantly following HCL initiation (p<0.001), falling from a mean of 82.5 mmol/mol at baseline to 72.8 mmol/mol within the first 3 months and remaining stable thereafter with a mean value of 69.3 mmol/mol at 12 months. Improvements were observed across all subgroups, with the greatest reductions in those with very high baseline HbA1c (>100 mmol/mol) and in participants transitioning from multiple daily injections. Outcomes were similar across HCL pump systems, and diabetes-related hospital admissions decreased overall following HCL initiation. CONCLUSIONS: In this large, real-world cohort of CYP with high HbA1c, initiation of HCL therapy was associated with sustained improvements in glycaemic control and fewer diabetes-related hospital admissions, supporting its use in this high-risk population.

来源:Arch Dis Child,查看原文。版权归原作者所有。

引用

  1. King AC, Christian P, Bassett P, et al. Real-world outcomes of hybrid closed-loop insulin pump therapy in UK children and young people with type 1 diabetes and high HbA1c: a multicentre retrospective cohort study. Arch Dis Child. 2026. PMID: 42309668. doi:10.1136/archdischild-2026-330408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。